Skip to Content


In the US, Tetrabenazine (tetrabenazine systemic) is a member of the drug class VMAT2 inhibitors and is used to treat Huntington's Disease and Tardive Dyskinesia.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Treatment of Huntington's disease

Vesicular monoamine transporter 2 (VMAT2) inhibitor

Chemical Names

(RS)-2,3,4,6,7,11b-Hexahydro-3-isobutyl-9-10-dimetoxy-1H-benzo[a]chinolizin-2-on (IUPAC)

1,2,3,4,6,7-hexahydro-3-isobutyl-9,10-dimetoxy-2-oxo-11bH-benzo[a]quinolizine (WHO)

1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimetoxy-2H-benzo[a]quinolizin-2-one (WHO)

2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimetoxy-

2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimetoxy-3-(2-metylpropyl)-


9,10-Dimetoxy-3-(2-metylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-one (BAN)

Foreign Names

  • Tetrabenazinum (Latin)
  • Tetrabenazin (German)
  • TĂ©trabĂ©nazine (French)
  • Tetrabenazina (Spanish)

Generic Names

  • Tetrabenazine (OS: BAN, JAN)
  • 5-21-13-00178 (IS: Beilstein)
  • AI3-52046 (IS)
  • BRN 0040090 (IS)
  • EINECS 200-383-6 (IS)
  • NSC 169886 (IS)
  • Ro 1-9569 (IS)

Brand Names

  • Choreazine
    Alfresa Pharma, Japan
  • Feinardon
    Tuteur, Argentina
  • Motetis
    AOP, Hungary; Douglas, New Zealand
  • Nitoman
    Cambridge, Taiwan; MediLink, Denmark; Temmler, Germany; UCB, Portugal; UCB Pharma, Spain; Valeant Pharmaceuticals International, Canada
  • PMS-Tetrabenazine
    Pharmascience, Canada
  • Revocon
    Capsifar, Portugal; LENIS, Slovenia; Sun Pharmaceuticals UK, United Kingdom; Tri Healthcare, Malta
  • Tetmodis
    AOP, Bosnia & Herzegowina; AOP Orphan Pharma, Estonia; AOP Orphan Pharmaceuticals, Austria; Axon Pharma, Chile; Beacon Pharmaceuticals, United Kingdom; Bluefish, France; Campus Pharma, Denmark; CampusPharma, Sweden; Cherubino, Malta; Desitin, Germany; Desitin Arzneimittel, Latvia; Orpha Devel, Netherlands; Orpha-Devel, Lithuania; Orpha-Devel, Poland; Orpha-Devel, Romania; Orpha-Devel, Slovenia; Orphan Europe, Portugal; Providens, Croatia (Hrvatska); Trommsdorff, Bulgaria
  • Tetrabenacina Lafedar
    Lafedar, Argentina
  • Tetrabenazine
    SteriMax, Canada; Valeant, Australia
  • Tetrabenazine AOP Orphan Pharmaceuticals
    AOP Orphan Pharmaceuticals, Belgium
  • Xenazina
    Chiesi Farmaceutici, Italy
  • Xenazine
    AFT, New Zealand; Curatis, Switzerland; EUSA Pharma, France; IFET, Greece; Lifehealth Limited, Israel; Lundbeck, United States; P & D, Malta; PharmaSwiss, Netherlands; PharmaSwiss, Poland


BANBritish Approved Name
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.